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ABSTRACT
Radioresistance is a major challenge for prostate cancer (CaP) metastasis and 
recurrence after radiotherapy. This study aimed to identify potential protein markers 
and signaling pathways associated with radioresistance using a PC-3 radioresistant 
(RR) subcutaneous xenograft mouse model and verify the radiosensitization 
effect from a selected potential candidate. PC-3RR and PC-3 xenograft tumors 
were established and differential protein expression profiles from two groups of 
xenografts were analyzed using liquid chromatography tandem-mass spectrometry. 
One selected glycolysis marker, lactate dehydrogenase A (LDHA) was validated, and 
further investigated for its role in CaP radioresistance. We found that 378 proteins 
and 51 pathways were significantly differentially expressed between PC-3RR and 
PC-3 xenograft tumors, and that the glycolysis pathway is closely linked with 
CaP radioresistance. In addition, we also demonstrated that knock down of LDHA 
with siRNA or inhibition of LDHA activity with a LDHA specific inhibitor (FX-11), 
could sensitize PC-3RR cells to radiotherapy with reduced epithelial-mesenchymal 
transition, hypoxia, DNA repair ability and autophagy, as well as increased DNA double 
strand breaks and apoptosis. In summary, we identified a list of potential RR protein 
markers and important signaling pathways from a PC-3RR xenograft mouse model, 
and demonstrate that targeting LDHA combined with radiotherapy could increase 
radiosensitivity in RR CaP cells, suggesting that LDHA is an ideal therapeutic target 
to develop combination therapy for overcoming CaP radioresistance.
                  Research Paper
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INTRODUCTION
Radiotherapy (RT) is a standard treatment option 
for both organ-confined and regionally advanced 
prostate cancer (CaP). Despite more and more effective 
advances in radiation delivery procedures, about 50% CaP 
patients undergoing RT suffer from relapse (recurrence) 
within 5 years of treatment [1]. Radioresistance (the 
failure to RT) is a major challenge for the current CaP 
RT. The mechanisms of cancer radioresistance are very 
complicated and affected by many factors, which severely 
affect radiation efficacy. One reason for these failures 
following RT is due to the intrinsic radioresistance of a 
subpopulation of clones within the tumor [2] while another 
reason could be the acquired radioresistance during RT [3, 
4]. Current markers used in clinics are not sufficient to 
separate radiosensitive CaP from radioresistant (RR) CaP 
to predict its radiation response and develop a personalized 
treatment. Therefore, it is important to identify therapeutic 
targets associated with CaP radioresistance and develop 
novel adjuvant treatments to cure the disease. If the 
potential targets for radiosensitization are identified 
and further validated, it will achieve a more favorable 
therapeutic ratio in clinics.
Due to considerable genetic, behavioral, and 
environmental heterogeneity, it is very difficult to discover 
and verify cancer biomarkers directly in human samples. 
Mouse model can be conducted under stringent genetic 
and environmental control for biomarker discovery and 
verification [5, 6]. The mouse model derived biomarkers, 
after validation in human patient’ sera, have been 
applied to develop multifactorial predictors of survival 
of castration-resistant CaP (CRPC) [7]. Therefore, the 
application of mouse models is highly promising for 
expanding our understanding of radioresistance, biomarker 
identification, and thereby moving closer to enhancing the 
prediction of radiosensitivity, and improving the treatment 
of RR cancer patients.
Using a low dose fractionated radiation treatment, 
we have recently developed CaP-RR cell lines with 
increased colony formation, invasion ability, sphere 
formation capability and enhanced epithelial-mesenchymal 
transition (EMT) and cancer stem cell (CSC) phenotypes 
and the activation of the PI3K/Akt/mTOR signaling 
pathway [8]. In the current study, one of the CaP-RR cell 
lines-PC-3RR, which was developed mimicking clinical 
conditions and representing the source of CaP recurrence 
after RT, was implanted subcutaneously in non-obese 
diabetic/severe combined immunodeficiency (NOD/SCID) 
mice and allowed to develop xenograft tumors in vivo. 
Comparing protein profiles of the RR tumor xenografts 
to the radiosensitive tumor xenografts provides an ideal 
model to investigate biomarkers and signaling pathways 
associated with CaP radioresistance.
In this study, we firstly identified differentially 
expressed proteins (DEPs) and a panel of pathways 
associated with CaP radioresistance from PC-3 and PC-
3RR xenografts using liquid chromatography tandem-
mass spectrometry (LC-MS/MS) technique and Ingenuity 
Pathway Analysis (IPA). In addition, a glycolysis 
marker lactate dehydrogenase A (LDHA), which is 
among the significant DEPs and sits in one of the most 
significantly deregulated pathways in radioresistance, 
was further validated in CaP-RR cell lines and PC-3RR 
xenograft tumors. LDHA is a main metabolic enzyme 
for lactate production which is a terminal product from 
glycolysis and plays an essential role in the glycolysis. 
We demonstrated that silencing of LDHA using the small 
interfering RNA (siRNA) or inhibition of LDHA with a 
small molecular inhibitor (FX-11) combined with RT 
reversed radioresistance in PC-3RR cells. Our findings 
have significant implications for developing novel 
therapies to overcome radioresistance and improve current 
CaP RT.
RESULTS
Establishment of the PC-3 and PC-3RR s.c 
xenograft models
PC-3 and PC-3RR subcutaneous (s.c) xenograft 
tumors were established and allowed to grow up to 7 
weeks. The growth rate of PC-3 and PC-3RR tumors 
at all time points and their tumor sizes at the end of the 
experiment did not show statistical difference (p>0.05) 
(Figure 1A and 1B). The tumor xenografts from these 
mice were collected at the end of experiment for 
immunohistochemistry (IHC) staining as well as for 
proteomics analysis.
Histological and IHC differences observed 
between PC-3 and PC-3RR s.c xenograft tumors
The histology (H&E staining) results from two 
animal xenografts indicate that the density of blood 
vessels in the PC-3RR tumors (as shown by the arrows) 
was increased compared to the PC-3 tumors (Figure 1C), 
suggesting the existence of higher levels of angiogenesis in 
PC-3RR model. The increased vasculature (angiogenesis) 
was further confirmed by CD31 and VEGFR2 staining 
(Figure 1C). Hypoxia marker HIF-1α was also found to 
be increased in the PC-3RR tumors compared to the PC-3 
tumors (Figure 1C). In addition, we also found enhanced 
EMT (increased N-Cadherin and reduced E-Cadherin) 
and CSC phenotypes (CD44 and Oct-4) in the PC-3RR 
xenograft tumors compared to the PC-3 control tumor 
(Figure 1C), which is consistent with our previous in vitro 
studies with CaP-RR cell lines [8]. The immunostaining 
intensity of IHC for CD31, VEGFR2, HIF-1α, EMT and 
CSC markers is summarized in Supplementary Table 
S1. These results suggest that PC-3RR xenograft tumor 
model retains phenotypic features of in vitro PC-3RR 
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cells [8] and is suitable for proteomic analysis of CaP-RR 
biomarkers.
Protein identification and quantification in PC-3 
and PC-3RR xenograft tumors
To investigate the DEPs in PC-3 and PC-3RR 
xenograft tumors, multivariate analysis of protein 
expression was performed using principal components 
analysis (PCA), according to abundance variation. It was 
demonstrated that PC-3 tumors clustered (the pink spots- 
left side) while PC-3RR tumors clustered (the blue spots-
right side) (Figure 2A). This demonstrates that 49% of the 
differences observed between these phenotypes can be 
attributed to the PC-3 xenografts vs PC-3RR xenografts. 
ANOVA p-values were used to determine DEPs. 
There were 378 proteins identified to be significantly 
differentially expressed between PC-3 and PC-3RR tumor 
xenograft samples (p<0.05) (Supplementary Table S2).
Network analysis and top canonical pathway 
terms in PC-3 and PC-3RR xenograft tumors
IPA was used to reveal the signaling networks 
and metabolic pathways enriched in the DEPs. Data 
from all DEPs were submitted in Ingenuity software 
for pathway analysis. Fifty one pathway terms that 
are significantly deregulated in PC-3RR tumours were 
identified (Supplementary Table S3). Thirty-seven of 
those are associated with CaP (Supplementary Table 
S3). The important pathways related with CaP include 
Glycolysis Metabolism, VEGF, and Epithelial Adherens 
Junction signaling pathways. Using IPA, the DEPs were 
clustered based on locations and functions performed 
(Figure 2B, 2C). Of the 378 DEPs identified from PC-3 
and PC-3RR paired xenografts, 271 proteins were mapped 
to pathways which were overly enriched in RR samples. 
The origin of these enriched pathway proteins includes 
148 cytoplasm (54.6%) and 37 nucleus (13.7%), 37 
Figure 1: Growth of PC-3 and PC-3RR tumors in vivo and IHC for vasculature, hypoxia, EMT and CSC markers in 
animal xenografts. A. The growth rates of PC-3 and PC-3RR s.c tumors. PC-3 and PC-3RR tumors were allowed to grow for 7 weeks. 
No significant difference was found for tumor growth between two models at all time points (p>0.05). B. At the end of the experiment, 
the tumor weights from PC-3 and PC-3RR groups of mice did not show significant difference (n=5, mean±SD, p>0.05). Representative 
images are shown for the tumor sizes in the two groups of mice. C. Histology and IHC evaluation of PC-3 and PC-3RR tumors. The cellular 
patterns and vasculatures (indicated by the white arrows) are shown in the H&E staining. CD31, VEGFR2, HIF-1α, N-Cadherin, CD44 
and Oct-4 were upregulated in PC-3RR xenografts while E-Cadherin was downregulated in PC-3RR xenografts. Brown indicates positive 
staining while blue indicates nuclei. Magnification x 400 in all images. Scale bar=50µm
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plasma membrane (13.7%) and 23 extracellular space 
(8.5%) (Figure 2B). The main cellular molecular functions 
of these DEPs include 73 enzymes (26.9%), 21 kinase/
peptidase/ phosphatases (7.7%), 21 transporters (7.7%), 
9 transcription regulators (3.3%), and 6 translation 
regulators (2.2%) (Figure 2C). These results indicate the 
DEPs identified have multiple functional roles in CaP 
radioresistance.
Examination of glycolysis pathway proteins in 
PC-3 and PC-3RR xenograft tumors
As glycolysis pathway was identified as an important 
signaling pathway from the proteomic analysis, we further 
validated the key proteins of this pathway in PC-3 and PC-
3RR xenograft tumors by IHC and Western blot. We found 
that the expression of the key glycolysis markers (GLUT-
1, PKM1/2 and LDHA) were significantly increased in 
PC-3RR xenografts compared with PC-3 xenografts and 
no positive staining for the detected markers was observed 
in the control sections (Figure 3A). The immunostaining 
intensity of glycolysis markers from IHC is summarized 
in Supplementary Table S1. The IHC results from PC-3 
and PC-3RR xenograft tumors were confirmed by Western 
blot (Figure 3B, 3C). These results further support that the 
glycolysis pathway is associated with CaP radioresistance.
Expression of LDHA in CaP RR cell lines and 
PC-3RR xenograft tumors
To further study the importance of glycolysis in CaP 
radioresistance, LDHA was chosen as a candidate for the 
functional validation. We demonstrated that increased 
expression of LDHA protein was found in CaP-RR (PC-
3RR, DU145RR and LNCaPRR) cells compared with CaP 
control cells (Figure 4A). The quantification of LDHA 
Western blot results from CaP and CaP-RR cell lines was 
presented in Figure 4B. The results were normalized by 
the level of β-actin and expressed as mean ± SD (n=3) 
(p<0.05). In addition, we also demonstrated the up-
Figure 2: Proteomics analysis using Progenesis QI and IPA. A. Principal component analysis (PCA) of global protein profiles 
in PC-3 and PC-3RR xenograft tumors. Principal component 1 (PC1) and principal component 2 (PC2) were plotted. The blue data points 
(Left) represent the samples from PC-3RR xenograft tumors, and the pink data points (Right) represent the samples from PC-3 xenograft 
tumors. The blue and red clusters were well separated. B. Ontology analysis of the significantly altered proteins between PC-3 and PC-3RR 
xenografts. Cellular compartments of the differentially expressed proteins in PC-3RR compared to PC-3 control xenografts. C. Ontology 
analysis of the significantly altered proteins between PC-3 and PC-3RR xenografts. Functions of the differentially expressed proteins in 
PC-3RR compared to PC-3 control xenografts.
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regulation of the LDHA protein in PC-3RR tumors by 
re-examining the protein levels of LDHA from LC-MS/
MS results using Progenesis QI software, (Figure 4C). 
Furthermore, increased expression of LDHA mRNA was 
also confirmed in PC-3RR xenograft tumors compared 
with PC-3 tumors using qRT-PCR (Figure 4D). All these 
results indicate LDHA could be a potential therapeutic 
target for CaP RT.
Radiosensitisation effect after knock down (KD) 
or inhibition of LDHA in PC-3RR cells
To investigate the role of LDHA in CaP RT, LDHA 
was knocked down in PC-3RR cells using siRNA (LDHA-
siRNA). The level of LDHA expression after KD was 
examined by Western blot. It was found that after 4 days 
of siRNA transfection, the cells became irregular and 
tended to detach from the bottom of the flask (data not 
shown) and that the maximum level of KD for LDHA was 
obtained at day 7 (D7) post siRNA transfection (Figure 
5A). Although the maximum KD effect was achieved 
at day 7, all experiments were performed at day 4 post 
siRNA transfection to retain the viability of cells. In 
addition to the LDHA-siRNA, the LDHA specific inhibitor 
FX-11 was also used to inhibit LDHA activity in vitro. 
The dose response of PC-3RR cells to FX-11 treatment 
was determined using an MTT assay (Figure 5B). IC
20
 
(0.1mM) for FX-11 from MTT assay was used for all 
following experiments.
To study the radiosensitization effect of KD or 
inhibition of LDHA using siRNA or FX-11 treatment, 
single RT or the combination of LDHA-siRNA (inhibitor 
FX-11) and RT treatments were performed for clonogenic 
ability (Figure 5C). It was found that the survival 
fractions at 4, 6, 8 Gy were significantly different between 
combinations of LDHA-siRNA/FX-11 inhibitor with RT 
and single RT controls (scr-siRNA or treatment with the 
equal volume of DMSO) in PC-3RR cells, respectively 
Figure 3: Validation of glycolysis proteins in PC-3 and PC-3RR xenografts. A. Validation of glycolysis proteins using IHC. 
The glycolysis pathway proteins GLUT-1, PKM1/2 and LDHA, were upregulated in PC-3RR xenografts compared to PC-3 xenografts. 
Brown indicates positive staining while blue indicates nuclei. Magnification x 400 in all images. B. Validation of glycolysis protein using 
Western blot. The upregulation of glycolysis pathway proteins GLUT-1, PKM1/2 and LDHA in PC-3RR xenografts were confirmed by 
Western blot. β-actin was used as a loading control. C. Quantification of Western blot results from PC-3 and PC-3RR xenografts. The results 
were normalized by the level of β-actin. Results are expressed as mean ± SD (n=3). “*” indicates: p<0.05. Scale bar=50µm.
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(p<0.05) (n=3), suggesting that KD or inhibition of LDHA 
led to markedly reduced clonogenic ability and sensitized 
PC-3RR cells to radiation.
Effects of LDHA KD or inhibition on reactive 
oxygen species (ROS)
As ROS plays an important role in radiation-
induced cellular damage and cancer radioresistance [9], 
we investigated whether ROS is involved in the LDHA-
siRNA and FX-11 mediated radiosensitization effects. Our 
results indicated that LDHA-siRNA or FX-11 treatment, 
combined with 6 Gy radiation, caused a significant 
increase of median fluorescence intensity (Figure 5D) and 
ROS levels (Figure 5E), compared to control groups in 
PC-3RR cells, respectively (p<0.05).
Effects of LDHA KD or LDHA inhibition on 
EMT, hypoxia, DSB, DNA repair pathway, 
apoptosis and autophagy proteins
To further investigate mechanisms of combination of 
LDHA-siRNA or FX-11 and RT on CaP radiosensitization, 
the representative markers associated with EMT, 
hypoxia, DSB (DNA double-strand breaks), NHEJ 
(non-homologous end-joining inhibitor), apoptosis and 
autophagy were assessed in PC-3RR cells with different 
treatments and control treatments including: scr-siRNA 
control, scr-siRNA+6 Gy RT, LDHA-siRNA, LDHA-
siRNA+6 Gy RT, vehicle control, vehicle control+6Gy RT, 
FX-11 and FX-11+6 Gy RT using Western blot.
Our results demonstrated that reduced N-Cadherin 
expression (EMT marker) was found in PC-3RR cells 
treated with LDHA-siRNA+RT and FX11+RT compared 
to the scr-siRNA and vehicle controls (Figure 6) while the 
suppression of LDHA with single LDHA-siRNA or FX-11 
treatments also reduced N-Cadherin expression in PC-3RR 
cells compared to controls (Figure 6), indicating EMT may 
be involved in radiosensitization caused by LDHA-siRNA 
or FX11 inhibition.
To assess the level of hypoxia in LDHA-siRNA 
or FX11 inhibitor treated cells, the HIF-1α was used 
as an indicator of hypoxia. We found that HIF-1α was 
significantly reduced in combination of LDHA-siRNA or 
FX-11 and RT compared to scr-siRNA+RT or vehicle+RT 
treated cells (Figure 6), indicating that hypoxia is 
associated with combination treatment with LDHA-siRNA 
or FX-11and RT.
Our results also showed that the levels of DNA 
DSBs marker-γH2AX were significantly increased in 
Figure 4: Expression of LDHA in CaP-RR cell lines and PC-3RR xenograft model. A. LDHA protein expression in CaP-RR 
cell lines. Higher levels of LDHA expression were seen in CaP-RR cell lines (PC-3RR, DU145-RR and LNCaP-RR) compared to their 
matching control cells.β-actin was used as a loading control. B. Quantification of Western blot results from CaP and CaP-RR cell lines. The 
results were normalized by the level of β-actin. Results are expressed as mean ± SD (n=3) (p<0.05). C. Abundance of LDHA was shown 
using Progenesis IQ software. D. Validation of LDHA mRNA in PC-3 and PC-3RR xenografts. LDHA mRNA levels were detected using 
qRT-PCR and was normalized to β-actin level. Significantly increased LDHA mRNA was associated with PC-3RR xenografts (p<0.05). 
“*” indicates: p<0.05.
Oncotarget74275www.impactjournals.com/oncotarget
LDHA-siRNA, LDHA-siRNA+RT, FX-11, FX-11+RT, 
treated PC-3RR cells compared to scr-siRNA and scr-
siRNA+RT or vehicle controls and vehicle+RT treated 
PC-3RR cells (Figure 6). Particularly, combination of 
LDHA-siRNA and RT significantly increased γH2AX 
level compared to vehicle+RT treatment and no obvious 
change was found between scr-siRNA or vehicle controls 
and scr-siRNA+RT or vehicle+RT treated cells (Figure 6), 
suggesting that there is a synergic effect by combination 
of LDHA-siRNA and RT in introducing DSBs in PC-3RR 
cells and improving radiosensitivity.
To evaluate the cellular response to DNA damage 
after RT, we examined the NHEJ DNA repair pathway 
protein Ku70 and found the level of Ku70 expression was 
significantly reduced in combination of LDHA-siRNA or 
FX-11 and RT compared to scr-siRNA+RT or vehicle+RT 
treatment (Figure 6), which is consistent with the DSB 
results and indicates the NHEJ DNA repair pathway plays 
an important role in combination of LDHA modulation or 
FX-11 inhibition and RT.
In addition, our results also indicated that single 
LDHA-siRNA or FX-11 treatment induced more apoptosis 
(increased Caspase-3-active) in PC-3RR cells compared 
to scr-siRNA or vehicle control and the combination of 
LDHA-siRNA/FX-11 and RT enhanced apoptosis to a 
higher extent (Figure 6). The findings of apoptosis by 
Western blot were confirmed by immunofluorescence 
staining (Supplementary Figure S1). Single LDHA-
siRNA KD or FX-11 treatment slightly suppressed 
autophagy (decreased Beclin-1 level) in PC-3RR cells 
compared to scr-siRNA or vehicle control, and the 
combination of LDHA-siRNA/FX-11 and RT reduced 
Beclin-1 to a lower extent compared with LDHA-siRNA 
or FX-11 treatment alone (Figure 6). These results suggest 
Figure 5: siRNA knocking down LDHA, MTT assay for FX-11 inhibitor, colony formation assay and ROS assay for 
single RT and combination treatments. A. siRNA knocking down LDHA. LDHA protein expression was observed at 1-7 days post 
LDHA-siRNA and scr-siRNA transfection. B. MTT assay for FX-11 inhibitor. PC-3RR cells were treated with FX-11 in final concentrations 
of 0-1 mM. The IC
20 
value was calculated to be 0.1mM. C. Colony formation assay. PC-3RR cells were treated with combination of 
LDHA-siRNA (scr-siRNA) or FX-11 (vehicle) with RT (2, 4, 6, and 8 Gy) for analysis of colony-forming efficiency. Survival fractions 
were significantly reduced in PC-3RR cells after LDHA-siRNA+RT or FX-11+RT treatments compared to control combination treatments 
(p<0.05 at 4, 6, 8 Gy). D. ROS analysis by flow cytometry. After specific combination treatments or control combination treatments, 
intracellular ROS production was measured by flow cytometry. As shown by the median fluorescent intensity, significantly higher levels 
of ROS were detected in combination of LDHA-siRNA and RT or FX-11 and RT in PC-3RR cells compared with scr-siRNA+RT or 
vehicle+RT (p<0.05). E. The representative image of histograms of ROS after single RT or combination treatments. All results were from 
three independent experiments (n=3). “*” indicates: p<0.05
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apoptosis and autophagy mechanisms are associated with 
LDHA downregulation or FX-11 inhibition mediated CaP 
radiosensitization. The changes of EMT, hypoxia, DSB, 
NHEJ, apoptosis, and autophagy pathway markers in PC-
3RR cells with different treatments are summarized in 
Table 1.
DISCUSSION
In the current study, we firstly developed PC-3RR 
s.c xenograft tumor model for proteomic biomarker 
discovery of interesting therapeutic targets. While there 
was no obvious difference in growth rates between PC-
Figure 6: The putative mechanisms of radiosensitisation caused by LDHA-siRNA downregulation or FX-11 inhibition 
in PC-3RR cells. Expression of N-Cadherin (EMT), HIF-1α (hypoxia), γH2AX (DNA DSB), Ku70 (DNA repair), Caspase-3 (active) 
(apoptosis) and Becline-1 (autophagy) was studied by Western blot after different treatments. The expressions of N-Cadherin and Becline-1 
were decreased in either LDHA-siRNA+RT or FX-11+RT treatment compared to scr-siRNA+RT or vehicle+RT, while the levels of γH2AX 
and caspase-3 (active) were increased in either LDHA-siRNA+RT or FX-11+RT treatment compared to scr-siRNA+RT or vehicle+RT. The 
levels of HIF-1α and Ku70 were significantly reduced after combination of LDHA-siRNA or FX-11 and RT treatment compared to RT plus 
vehicle treatment. β-actin was used as a loading control. Note: “caspase-3 (a)” indicates caspase-3 (active)”
Table 1: The changes of EMT, hypoxia, DSB, NHEJ, apoptosis, and autophagy pathway markers in PC-3RR cells with 
different treatments
Pathway/
function
LDHA-siRNA 
vs scr-siRNA
LDHA-
siRNA+RT vs 
LDHA-siRNA
LDHA-
siRNA+RT vs 
scr-siRNA+RT
FX-11 vs 
vehicle control
FX-11+RT 
vs FX-11
FX-11+RT 
vs vehicle 
control+RT
EMT 
(N-Cadherin)
- + - - + -
Hypoxia (HIF-α) - - - = + -
DSB (γH2AX) + = + + + +
NHEJ (Ku70) - - - = - -
Apoptosis 
(Caspase-3-
active)
+ + + + + +
Autophagy 
(Becline-1)
- - - - - -
Notes: “+” pathway is enhanced; “-” pathways is suppressed; “=” no significant change. The results are from three 
independent experiments.
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3RR tumors and PC-3 control tumors, the PC-3RR tumors 
were less responsive to radiation treatment compared 
to PC-3 control tumors (unpublished observation), 
suggesting that the RR characteristics were retained 
in the PC-3RR xenografts in vivo. It is well known 
that angiogenesis, hypoxia, EMT and CSC play very 
important roles in cancer radioresistance [10]. In PC-
3RR tumors, we demonstrated increased angiogenesis 
(CD31 and VEGFR2) and hypoxia (HIF-1α) as well 
as enhanced EMT (increased N-Cadherin and reduced 
E-Cadherin) and elevated CSC markers’ expression 
(CD44 and Oct-4), which is consistent with our previous 
in vitro study in CaP-RR cells [8], further confirming that 
angiogenesis, hypoxia, EMT and CSC are involved in CaP 
radioresistance and this model is very suitable for studying 
CaP radioresistance.
With LC-MS/MS analysis, 378 DEPs were 
identified between PC-3 and PC-3RR tumor xenografts. 
PCA data indicated a satisfactory separation of two 
groups of samples from PC-3 and PC-3RR xenograft 
tumors. Pathway enrichment analysis could demonstrate 
51 pathways to be deregulated in PC-3RR tumors. Among 
them, 37 pathways are reported to be associated with CaP 
using Pubmed (http://www.ncbi.nlm.nih.gov/pubmed) 
database search. Our results indicate that top five pathways 
associated with CaP radioresistance (ordered according 
to the number of CaP related publications from Pubmed 
database) are: VEGF signaling, Integrin signaling, IGF-
1 signaling, Glycolysis I and Protein Kinase A signaling. 
These findings suggest that CaP radioresistance is 
regulated by a multiple protein network and various 
important signaling pathways, and that management 
of these proteins or signaling pathways is promising to 
develop novel therapies to improve CaP RT.
A number of studies have demonstrated that 
increased aerobic tumor metabolism (glycolysis) 
is highly associated with the development of 
radioresistance by providing a chemically reduced 
milieu in the tumor microenvironment [11] and 
inhibition of glycolysis resulted in increased 
radiosensitivity [12]. The roles of glycolysis in CaP 
radioresistance are still unclear. Due to the importance 
of glycolysis in cancer radioresistance and its close 
link with angiogenesis, hypoxia, EMT and CSC [13-
17], this pathway was chosen for further validation. It 
was found that the key glycolysis pathway proteins-
GLUT-1, PKM1/2 and LDHA were increased in PC-
3RR xenograft tumors compared to PC-3 tumors, 
further confirming the activation of glycolysis pathway 
in CaP radioresistance.
LDHA is a main metabolic enzyme for lactate 
production which is a terminal product from glycolysis. 
It is one of the important glycolysis pathway proteins 
which catalyzes the inter-conversion of pyruvate and 
lactate. Several lines of evidence indicate that elevated 
levels of LDHA correlate with a higher grade of aerobic 
glycolysis and with poor prognosis in cancers [18-21]. It 
was reported that the high levels of lactate and LDHA are 
associated with poor response to radiation treatments in 
head and neck squamous cell carcinoma (HNSCC) [22, 
23]. Yamada et al. found that high level of serum LDHA 
is indicative of poor prognosis in CaP [24]. Koukourakis 
et al. conducted a study on 83 human CaP biopsies and 
found that LDH5, an isoform encoded by LDHA gene, 
is significantly associated with biomedical failure after 
RT [25], indicating that LDH family is associated with 
CaP radioresistance. The current study demonstrated 
that higher levels of LDHA expression were found in 
CaP-RR cells and PC-3RR xenograft tumors, suggesting 
that LDHA could be a hallmark in CaP radioresistance, 
and LDHA down-regulation and inhibition both lead to 
radiosensitization of CaP-RR cells, which is consistent 
with the result of LDH5 by Koukourakis et al [25]. The 
role of LDHA in CaP radioresistance is still unclear. 
Therefore, a series of functional studies were performed to 
investigate the mechanisms and pathways that are involved 
in the LDHA reduction mediated CaP radiosensitization.
ROS has an important implication in cancer 
radioresistance [9]. As a key event in RT-induced 
biological processes, it is widely involved in DNA 
damage, cell cycle arrest and apoptosis [26]. In this 
study, we found knocking down LDHA using siRNA 
or treatment with a specific LDHA inhibitor FX-11 
combined with RT could increase radiosensitivity in PC-
3RR cells accompanied with increased ROS, which is in 
line with the findings in CaP cell lines treated with LDHA 
siRNA or LDHA inhibitor by Koukourakis et al [25]. A 
previous report demonstrated that driving glycolysis and 
degradation of glucose to lactate supports diminishing 
of oxidative stress [27]. KD of LDHA was reported to 
contribute to the increase of mitochondrial ROS, because 
of the redirection of metabolism away from lactate as the 
end product, favouring rather the conversion of pyruvate 
to acetyl-coA and entering the TCA cycle in mitochondria 
for breast cancer [28]. It was shown that FX-11 treatment 
induces oxidative stress and cell death in the P493 
human lymphoma B cells in vitro and inhibited human 
lymphoma progression [29]. These results suggest that 
LDHA modulation-induced radiosensitization might partly 
result from ROS. Therefore, reduction of LDHA-mediated 
glycolysis in this study could be regarded as a driver of 
oxygen consumption, which resulted in high level of ROS, 
and increased ROS in combination treatment can lead to 
cell death [29].
Our recent study demonstrated that EMT could be 
a factor leading to the acquisition of CaP radioresistance 
[8]. Shintani et al. also found that increased EMT is 
associated with resistance of non-small cell lung cancer 
(NSCLC) to RT or chemotherapy [30]. Kim et al. reported 
that microRNA (miR)-34a mediated targeting of EMT 
increased in vivo radiosensitivity in a NSCLC xenograft 
mouse model [31]. In the current study, we showed that 
Oncotarget74278www.impactjournals.com/oncotarget
single LDHA-siRNA or FX-11 inhibition resulted in 
reduction of EMT, and combination treatments reduced 
EMT compared to single RT, suggesting that reversal of 
EMT by LDHA modulation could be another possible 
mechanism for radiosensitizaion in CaP-RR cells.
HIF-1α is stabilized and accumulated under 
hypoxia. Ample evidence showed that it up-regulates 
glycolysis genes [32] including LDHA in CaP [33]. An 
earlier study proved a hypoxia response element was 
present in the promoter region of the LDHA gene [34]. KD 
of LDHA and HIF-1α was reported to restore sensitivity 
to a chemodrug on multiple myeloma cell lines [35]. 
Hypoxic cells are believed to be more resistant to radiation 
treatment compared to non-hypoxic cells [36]. When 
normoxia is dominant rather than hypoxia, activation of 
various tumor survival and angiogenesis genes is inhibited 
[29]. Reoxygenation after RT is regarded to improve the 
outcome of RT [37]. Inhibition of LDHA in human P493 
B-lymphoid cells resulted in inhibition of hypoxia [29], 
indicating LDHA and hypoxia are correlated. In this study, 
we showed that the HIF-1α was downregulated by LDHA-
siRNA combined with RT, suggesting hypoxia could be 
suppressed by reduced LDHA, thus leading to inhibition 
of tumor survival genes and promoting radiosensitization.
A critical marker of RT-induced DNA DSBs is the 
phosphorylation of histone γH2AX [38], which is an 
indicator of the DSB repair ability after RT [39]. Escalated 
DSB was observed in PC-3RR cells at both LDHA KD 
and inhibition of LDHA alone. Combination of LDHA KD 
or inhibition with RT, further increased DSB in PC-3RR 
cells compared to RT treatment alone. Furthermore, the 
DNA DSB repair via NHEJ pathway, as indicated by Ku70 
level, was significantly abrogated in LDHA KD, or even 
depleted in the LDHA KD plus RT treated cells. However, 
the impaired NHEJ DNA repair mechanism was not 
obvious in FX-11 treatments as in LDHA KD, suggesting 
LDHA inhibition by FX-11 does not completely confer 
DNA repair ability through NHEJ pathway, and the FX-
11 treated cells still retain DNA repair ability via other 
pathways.
Apoptosis has a crucial role in cell death after RT, 
and autophagy is called as ‘the second apoptosis’. In 
cancer therapy, the role of autophagy is paradoxical, in 
which this cellular process may serve as a pro-survival 
or pro-death mechanism to counteract or mediate the 
cytotoxic effect of anticancer agents [40]. Le et al. 
found that silencing or inhibition of LDHA increased 
apoptosis possibly via induced oxidative stress [29]. As 
previous described, targeting autophagy was considered 
as an effective way of overcoming radioresistance [41]. 
Meng et al. demonstrated that silencing PKM2 in the 
glycolysis pathway was shown to sensitize RT in NSCLC 
via inhibiting autophagy [12]. It was also reported that 
inhibition of autophagy by rapamycin and apoptosis 
inducer could effectively sensitize a lung cancer cell line 
to radiation [42]. In this study, we found that combination 
of LDHA-siRNA or FX-11 inhibitor with RT both 
markedly increased apoptosis and reduced autophagy 
level, suggesting that both apoptosis and autophagy are 
involved in CaP radiosensitization effect.
The functional studies have proved that LDHA 
KD or inhibition can lead to the changes of ROS, EMT, 
hypoxia, DSB, apoptosis and autophagy, thus resulting 
in the sensitization of CaP RR cells. Because of its tight 
linkage to different pathways, LDHA is revealed to be not 
only a hallmark of CaP radioresistance but also a favorable 
target for radiosensitization treatment of the CaP-RR 
patients.
In summary, in this study, we have identified a list 
of potential RR markers and important signaling pathways 
from PC-3RR xenograft mouse model, and found 
that LDHA is a potential therapeutic target associated 
with CaP radioresistance. In addition, we demonstrate 
that the radiosensitization effect of combination of 
interfering LDHA with RT is associated with enhanced 
ROS, apoptosis and DSBs as well as reduced EMT and 
autophagy. Our findings suggest that LDHA is an ideal 
therapeutic target to develop combination therapy to 
overcome CaP radioresistance.
MATERIALS AND METHODS
Cell lines and cell culture
PC-3, DU145, LNCaP cell lines were obtained from 
American Type Culture Collection (ATCC) (Rockville, 
MD, USA). PC-3RR, DU145RR, and LNCaPRR cell 
lines were developed and the confirmed in our previous 
study [8]. All cell lines used were cultured in RPMI-1640 
medium supplemented with 10% heated-inactivated fetal 
bovine serum (FBS), 50 U/mL of penicillin and 50 µg/
mL of streptomycin. All cell lines were maintained in a 
humidified incubator at 37°C and 5% CO
2
. The identities 
of all cell lines were confirmed by short tandem repeat 
profiling. All cell lines were regularly tested to confirm 
the absence of mycoplasma contamination using the 
LookOut® mycoplasma PCR detection kit (Sigma-Aldrich 
Pty Ltd, NSW, Australia).
Antibodies
Antibodies were obtained from different sources. 
The detailed information and conditions for all antibodies 
are listed in Table 2.
Establishment of PC-3 and PC-3RR animal 
xenograft models in vivo
Seven weeks male NOD/SCID mice (Animal 
Resources Centre, Western Australia) were housed under 
specific pathogen-free conditions in facilities approved 
by the University of New South Wales (UNSW) Animal 
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Table 2: Antibodies used for western blot (WB), immunofluorescence (IF) and immunohistochemistry (IHC) 
staining
Antibody Source Type Dilution Incubation 
time
Temperature Application
Rabbit anti-E-Cadherin antibody Abcam PAb 1:100 O/N 4°C IHC
Rabbit anti-human N-Cadherin 
antibody
Abcam PAb 1:500 O/N 4°C IHC,WB
Rabbit anti-human Ku70 
antibody
Abcam PAb 1:1000 O/N 4°C WB
Rabbit anti-human γH2AX 
antibody
Abcam PAb 1:1000 O/N 4oC WB
Rabbit anti-human active 
Caspase-3 antibody
Abcam PAb 1:500 O/N 4°C WB
Rabbit anti-Becline-1 antibody Cell signalling 
Technology
PAb 1:1000 (WB) O/N 4°C WB
Rabbit anti-human Becline-1 
antibody
Cell signalling 
Technology
PAb 1:1000 O/N 4°C WB
Mouse anti-human Beta-actin 
antibody
Sigma Altrich MAb 1:5000 O/N 4°C WB
Rat anti-mouse CD31 antibody BD pharmingen MAb 1:100 O/N 4°C IHC
Rabbit anti-VEGFR2 antibody Abcam PAb 1:100 O/N 4°C IHC
Mouse anti-CD44 antibody Santa Cruz 
Biotechnology
MAb 1:200 O/N 4°C IHC
Rabbit anti-Oct4 antibody Abcam PAb 1:500 O/N 4°C IHC
Mouse anti-human HIF-1α 
antibody
Abcam MAb 1:500 (WB) 
1:100 (IHC)
O/N 4°C IHC, WB
Rabbit anti-human PKM1/2 
antibody
Cell signalling PAb 1:1000 (WB) 
1:100 (IHC)
O/N 4°C IHC, WB
Rabbit anti-human GLUT-1 
antibody
Abcam PAb 1:1000 (WB) 
1:100 (IHC)
O/N 4°C IHC, WB
Rabbit anti-human LDHA 
antibody
Abcam PAb 1:2000 (WB) 
1:400 (IHC)
O/N 4°C IHC, WB
Goat anti-rabbit Alexa Fluor® 
488 Dye Conjugate
Invitrogen IgG 1:1000 (IF) 60 mins rt IF
Goat anti-rabbit IgG-HRP Santa Cruz 
Biotechnology
PAb 1:2000 45 mins rt WB
Goat anti-mouse IgG-HRP Santa Cruz 
Biotechnology
PAb 1:2000 45 mins rt WB
Rabbit anti-rat 
immunoglobulins, biotinlyated
Dako Pty. Ltd. PAb 1:100 45 mins rt IHC
Goat anti-rabbit IgG-HRP Dako Pty. Ltd. PAb 1:100 45 mins rt IHC
Rabbit anti-mouse IgG-HRP Dako Pty. Ltd. PAb 1:100 45 mins rt IHC
(Continued )
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Care and Ethics Committee (ACEC) (ACEC 13/118B). 
Mice were kept at least 1 week before experimental 
manipulation. All mice remained healthy and active during 
the experiments. The CaP s.c model was established 
following our published method [43]. Briefly, cultured 
PC-3 and PC-3RR cells (2 x 106/injection) in 100 uL 
Dulbecco’s Phosphate-Buffered Saline (DPBS) were 
implanted subcutaneously in the right rear flank region 
of mice (n=5 mice/per group). Tumor progression was 
documented weekly by measuring tumor sizes using 
callipers. Tumor volumes were calculated as follows: 
length x width x height x 0.52 (in millimetres) [44].
For growth rate study, the mice were euthanized 7 
weeks post cell inoculation. For each tumor, half were 
snap-frozen using liquid nitrogen for proteomics study 
and the rest separated for paraffin embedding and frozen 
sectioning for histological examination and IHC.
Preparation of protein samples for LC-MS/MS
Frozen PC-3 or PC-3RR xenograft tissues were 
minced with stainless steel scalpels. The mince tissues 
were then ground in liquid nitrogen in a mortar using a 
pestle. The tissue powder was resuspended using lysis 
buffer (50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L 
NaCl, 0.1% sodium dodecyl sulfate (SDS), 10 mmol/L 
NaF, 1 mmol/L Na
3
VO4, 0.5% sodium deoxycholate 
and 1% Triton X-100) at a ratio of 1 mg tissue:5 mL 
buffer, followed by a bead beating method. Briefly, 0.13g 
zirconium beads (0.1 mm diameter)/100 µL of lysis buffer 
were added into mixture, and bead beating was performed 
on the highest setting for 80 seconds and returned to ice 
for 5 mins. Bead beating was repeated 4 times. Solution 
was centrifuged at 30000g for 40 min and the supernatant 
was collected. Protein concentration was determined by 
the BCA protein assay kit (Pierce, USA). Protein samples 
were digested according to a published method [45]. 
A total of 100 µg of total cell lysate from each sample 
was precipitated in 100% ice-cold acetone at 1:4 (v/v) 
protein solution:acetone dilution. Trypsin (in 50 mM 
ammonium bicarbonate buffer, pH 8.5) was added at an 
enzyme/substrate ratio of 1:100 (w/w) and the samples 
were incubated overnight (o/n) to allow for digestion. The 
lyophilized samples were eluted by using C18 stage tips 
and collected in mass spectrometry tubes.
LC-MS/MS
LC-MS/MS analysis was carried out for PC-3 
and PC-3RR xenograft samples using an LTQ Orbitrap 
Velos ETD (Thermo Scientific, US) at Bioanalytical 
Mass Spectrometry Facility (BMSF), UNSW. Digested 
peptides were reconstituted in 10 µL 0.1% formic acid 
and separated by nano-LC using an Ultimate 3000 HPLC 
and autosampler (Dionex, Amsterdam, Netherlands). The 
sample (0.2 µL) was loaded onto a micro C18 pre-column 
(300µm×5mm, Dionex, Scoresby, VIC, Australia) with 
Buffer A (98% H
2
O, 2% CH
3
CN, 0.1% TFA) at 10 µL/
min. After washing, the pre-column was switched (Valco 
10 port valve, Dionex) into line with a fritless nano column 
(75 µm i.d × 15cm) containing reverse phase C18 media 
(3 µm, 200 Å Magic, Michrom Bioresoures). Peptides 
were eluted using a linear gradient of Buffer A to Buffer 
B (98% CH
3
CH, 2% H
2
O, 0.1% formic acid) at 0.25 µL/
min over 60 min. High voltage (2000V) was applied to 
low volume tee (Upchurch Scientific, Oak Harbor, WA, 
USA) and the column tip positioned 0.5 cm from the 
heated capillary (T=280°C) of an Orbitrap Velos (Thermo 
Electron, Bremen, Germany) mass spectrometer. Positive 
ions were generated by electrospray and the Orbitrap was 
operated in a data-dependent acquisition (DDA) mode. A 
survey scan 350-1750 m/z was acquired in the Orbitrap 
(Resolution=30000 at 400 m/z, with an accumulation 
target value of 1000000 ions) with lockmass enabled. Up 
to the 10 most abundant ions (>5000 counts) with charge 
states +2 to +4 were sequentially isolated and fragmented 
within the linear ion trap using collisionally induced 
dissociation with an activation q=0.25 and activation time 
of 30 ms at a target value of 30000 ions. The m/z ratios 
selected for MS/MS were dynamically excluded for 30s 
[46].
Progenesis QI analysis
MS peak intensities were analyzed using Progenesis 
QI data analysis software v4 (Waters). Ion intensity maps 
from each run were aligned to a reference sample and 
ion feature matching was achieved by aligning consistent 
ion m/z and retention times. The peptide intensities 
were normalized against total intensity (sample specific 
log-scale abundance ratio scaling factor) and compared 
Antibody Source Type Dilution Incubation 
time
Temperature Application
Mouse anti-human IgG1-
negative
Dako Pty. Ltd. IgG 1:100 O/N 4°C IHC
Rabbit anti-human IgG1-
negative
Dako Pty. Ltd. IgG 1:100 O/N 4°C IHC
Notes: HRP: horseradish peroxide;IF: immunofluorescence;IHC: immunohistochemistry; MAb: monoclonal antibody; 
O/N: overnight; PAb: polyclonal antibody; rt: room temperature; WB: Western Blot.
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between groups by one-way analysis of variance 
(ANOVA, p≤0.05 for statistical significance) and post 
hoc multiple comparison procedures. Type I errors were 
controlled by False Discovery Rate (FDR) with q value 
significance set at 0.01 [47]. Results are reported as mean 
± SD (normalized ion intensity score).
Protein dataset
Peak lists of proteins were generated using Mascot 
Daemon/extract_msn (Matrix Science, Thermo, London, 
UK) using the default parameters, and submitted to Mascot 
2.1 (Matrix Science). All MS/MS spectra of differentiating 
peptides were searched against human non-redundant 
NCBInr database using the Mascot search program (Matrix 
Science, London, UK, www.matrixscience.com) for protein 
identification with the following criteria: (1) species, Homo 
sapiens; (2) allowed one missed cleavage; (3) variable 
modifications, Oxidation (M), Phospho (ST) and Phospho 
(Y); (4) peptide tolerance, ±6 ppm; (5) MS/MS tolerance, 
± 0.6Da; (6) peptide +2, +3 and +4; and (7) enzyme 
specificity, none. The results were imported into Progenesis 
QI LC-MS software and peptides were considered to be 
confidently identified when matches had a high ion score 
>20 and peptides were assigned to a protein.
Ingenuity
IPA (Ingenuity® Systems, www.ingenuity.com) 
was used to assess pathways of differentially regulated 
proteins. The accession numbers of DEPs, average 
normalized abundances, fold changes and p-values were 
submitted to IPA. The protein pathways and the terms 
were identified through IPA database search.
Immunohistochemistry
Paraffin sections of xenograft tumors were used for 
IHC staining of angiogenesis, EMT, CSC and glycolysis 
markers as well as for H&E staining (tumor histology). 
All staining was performed following our previously 
published methods [48, 49]. Briefly, paraffin sections 
were de-paraffinized and rehydrated, then incubated with 
primary antibodies o/n at 4 °C. Slides were then incubated 
with rabbit anti-mouse or goat anti-rabbit IgG/HRP second 
antibody (1:100 dilution) for 45 min. Frozen 5µM sections 
of xenograft tumors were used for CD31 and CD44 
staining to examine the micro-vessel density (MVD) and 
CSC. Sections were incubated with rat anti-mouse CD31 
or mouse anti-human CD44 monoclonal antibody (MAb) 
(1:100 dilution) o/n at 4°C then incubated with rabbit 
anti-rat HRP or Goat anti-mouse HRP (1:100 dilution) 
for 45 min at room temperature. All sections were finally 
developed with 3,3’ diaminobenzidine (DAB) substrate 
solution (Sigma-Aldrich, Pty Ltd, Castle Hills, NSW, 
Australia), then counterstained with hematoxylin (Thermo 
Fisher Pty Ltd, VIC, Australia). Control slides were treated 
in an identical manner, by using isotype antibodies or 
omitting primary antibody as a negative control.
RNA extraction and qRT-PCR
Approximately 1mg of tumors from PC-3 and 
PC-3RR xenografts was collected and ground in liquid 
nitrogen. Immediately after liquid nitrogen evaporated, the 
total RNA was extracted and purified using the RNeasy 
Plus Mini Kit (Qiagen, VIC, Australia) according to 
the manufacturer’s instructions. The concentrations of 
total RNA from tissues were measured by a ND-2000 
NanoDrop spectrophotometer (NanoDrop Technologies, 
Wilmington, DE). Two micrograms (mg) of total RNA 
from each sample were reverse transcribed to cDNA 
using the SuperScript III First-strand Synthesis System 
Kit (Invitrogen Pty Ltd, VIC, Australia), according to 
the manufacturers protocol. All mRNA expression of the 
LDHA and β-actin gene was assessed using qRT-PCR. A 
Rotor-Gene instrument (Corbett Life Science, Sydney, 
Australia) was used for automated qRT-PCR setup of the 
reactions. After three independent experiments, the REST 
2009 V2.0.13 (Qiagen, VIC, Australia) software was used 
for calculation and analysis of LDHA gene expression.
LDHA siRNA transfection
Silencer Select LDHA siRNAs and Negative Control 
scramble scr-siRNA were purchased from Invitrogen 
(Invitrogen Australia Pty Ltd, Melbourne, VIC, Australia). 
Transfection was performed by incubating the cells with 
LDHA-siRNA or scr-siRNA and LipofectAMINE 2000 at 
37°C for 1-7 days, following the manufacturer’s protocol. For 
all functional studies, LDHA-siRNA was used for 4 days to 
achieve the best KD effect and maintain a healthy status of 
the cells.
Cytotoxicity of FX-11
FX-11 (a LDHA inhibitor) was purchased from 
Merck Millipore (VIC, Australia) and dissolved in DMSO. 
Cytotoxicity of FX-11 was evaluated on PC-3RR cells 
using an MTT assay following a published method [48]. 
Briefly, 2000 cells were seeded in 96-well plates incubated 
in culture media for 24 h. Cells were then treated with a 
range of concentrations of FX-11 (0–1 mM) or the same 
volume of DMSO as the vehicle control in fresh media for 
48 h. The absorbance (OD) was read at 560 nm on a BIO-
TEC micro-plate reader (BIO-RAD, Hercules, CA, USA). 
The IC
20
 value (20% inhibitory concentration) of FX-11 
was calculated and chosen for the following experiments.
Colony formation assay
PC-3RR cells with different treatments including 
scr-siRNA control, LDHA-siRNA, DMSO vehicle control 
and FX-11 were seeded for a clonogenic survival assay 
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following exposure to different dose of radiations 0, 2, 
4, 6, and 8 Gy. Different numbers of cells were seeded 
in 6 well plates in triplicates: 500 cells for 0 Gy, 1000 
cells for 2 Gy, 2000 cells for 4 Gy, 4000 cells for 6 Gy, 
and 8000 cells for 8 Gy. After irradiation, the cells were 
cultured for 14 days and the number of surviving colonies 
(defined as a colony with >50 cells) were counted. Data 
from radiation-treated cells were normalized against the 
untreated cells (scored as 100% colony forming ability). 
Plating efficiencies and survival fractions were calculated 
to obtain survival parameters and plot cell survival curves.
ROS assay
Intracellular ROS was measured by flow cytometry. 
The semi-confluent cells (0.5~1 x 106) in 25cm2 flasks 
were treated with scr-siRNA, LDHA-siRNA, DMOS 
vehicle and FX-11, after 90 hours of scr-siRNA and LDHA-
siRNA treatments or 42 hours of DMSO vehicle and FX-
11 treatments, the cells were irradiated at 6 Gy. At 6 hours 
post RT, culture media was replaced with CellROX Green 
Reagent (Molecular Probes; MA USA) solution (1:1000 in 
plain RPMI-1640) and was incubated for 20 min. Following 
detachment and washing, cells were analyzed using a FACS 
Canto II Flow Cytometer (Becton, Dickinson and Company, 
BD Biosciences, San Jose, USA).
Western blot
Cultured PC-3RR cells in 25 cm2 flasks were treated 
with scr-siRNA, scr-siRNA+RT, LDHA-siRNA, LDHA-
siRNA+RT, vehicle control, vehicle control+RT, FX-11, 
FX-11+RT. There was a 90 hours interval between LDHA-
siRNA/scr-siRNA and RT treatments or a 42 hours interval 
between FX-11/vehicle control and RT treatments. At 6 
hours post RT treatments, proteins were extracted. Protein 
expression levels were determined by Western blot analysis 
as described [48]. Briefly, whole cell lysates were separated 
by NuPAGE Novex 4–12% Bis-Tris gel electrophoresis and 
then transferred to polyvinylidene difluoride membrane. 
After blocking non-specific sites with 5% bovine serum 
albumin, the membrane was incubated with different 
primary antibodies (see Table 2), followed by incubation 
with HRP-conjugated secondary antibodies (goat anti-
mouse or goat anti-rabbit appropriate for the host species 
of the primary antibody) (1:2000 dilution). Immunoreactive 
bands were detected using enhanced chemiluminescence 
(ECL) substrate (Pierce Chemical Co, Rockford, USA), and 
imaged using the ImageQuant LAS4000 system (GE Health 
care, USA). To confirm equal loading of protein lysates, 
membranes were re-probed using mouse anti-human β-actin 
antibody (1:5000 dilution), then processed as above.
Immunofluorescent staining
Immunofluorescence staining was performed as 
previously described [8]. Briefly, the cultured PC-3RR 
cells with different treatments as mentioned above in 
Western blotting were cytospined at room temperature 
and then incubated with 10% normal goat serum in TBS 
for 20 min to suppress the nonspecific binding of IgG. 
The cells were then incubated with anti-caspase-3-active 
(1:500) o/n at 4 ºC. After rinsing in TBS, cells were 
incubated for 45 min in goat anti-rabbit Alexa Fluor-488 
conjugate secondary antibodies (1:1000 dilutions) at 
room temperature. Propidium iodide (PI) (0.2 mg/L) was 
used to stain the nuclei. Negative controls were treated 
identically but omitted with the primary antibodies. 
Immunofluorescence was visualized using an FV 300/
FV500 Olympus laser scanning confocal microscope 
(Olympus).
Detection of apoptosis using acridineorange/
ethidium bromide (AO/EB) staining
The cultured PC-3RR cells with different treatments 
as mentioned above in Western blot were prepared for 
detection of apoptosis by AO/EB staining using our 
published method [50].
Statistical analysis
ANOVA was used in progenesis QI analysis. All 
experiments were performed at least three times and 
data was presented as the mean±standard deviation 
(SD), unless otherwise indicated. Data from different 
groups were compared using the two-tail student’s 
t test. All p values were two-sided. p<0.05 was 
considered significant. The statistical analysis of 
immunostaining intensity in animal xenografts was 
performed as described in our previous publication 
[51]. All numerical statistical analyses were performed 
using the GraphPad Prism 6 package (GraphPad, CA, 
USA).
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